ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,673.75
0.41%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Noticias

ARQT Arcutis Biotherapeutics Inc

8.31
-0.28 (-3.26%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Arcutis Biotherapeutics Inc ARQT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.28 -3.26% 8.31 23:00:05
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.59 8.36 8.85 8.47 8.59
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
10/4/202407:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05/4/202415:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/4/202406:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/3/202407:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/3/202407:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10/3/202415:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09/3/202415:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
06/3/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04/3/202416:47EDGAR2Form 144 - Report of proposed sale of securities
04/3/202416:42EDGAR2Form 144 - Report of proposed sale of securities
04/3/202416:40EDGAR2Form 144 - Report of proposed sale of securities
04/3/202415:10EDGAR2Form 8-K - Current report
04/3/202415:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/3/202407:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
01/3/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202415:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202416:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
28/2/202422:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28/2/202415:54EDGAR2Form 144 - Report of proposed sale of securities
28/2/202415:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202415:10EDGAR2Form 8-K - Current report
28/2/202415:10GLOBEArcutis Announces Proposed Public Offering
28/2/202415:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27/2/202415:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202406:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202406:44EDGAR2Form 8-K - Current report
27/2/202404:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16/2/202407:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
15/2/202417:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202417:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:20EDGAR2Form 8-K - Current report
15/2/202415:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
13/2/202408:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
08/2/202415:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202415:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
31/1/202416:22EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202407:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
29/1/202407:00GLOBEJournal of the American Academy of Dermatology Publishes..
24/1/202415:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
22/1/202407:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
17/1/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/1/202403:00GLOBEMajority of Individuals with Atopic Dermatitis Improved with..

Su Consulta Reciente

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados